COVID19 associated pulmonary aspergillosis

Clinical Microbiology and Antimicrobial Chemotherapy. 2021; 23(3):239-246

​ Ovsyannikov N.V., Bilevich O.A.
10.36488/cmac.2021.3.239-246
COVID-19 complications invasive aspergillosis risk factors
Section
Diseases and Pathogens
Type
Review
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2021; 23(3):239-246

Abstract

The novel coronavirus (COVID-19) pandemic announced by the World Health Organization in March 2020 assigned medical community to the new tasks that require immediate solutions. Recent studies have shown that invasive aspergillosis associated with COVID-19 often complicates a course of the disease and leads to death. This review aims to describe the diagnosis and therapy challenges due to COVID-19 associated invasive pulmonary aspergillosis.

Ovsyannikov N.V.

Omsk State Medical University, Omsk, Russia

Olga A. Bilevich

Omsk State Medical University, Omsk, Russia

  • 1. World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. Available at: https://covid19.who.int. Accessed March 03, 2021.
  • 2. Lu R., Zhao X., Li J. Niu P., Yang B., Wu H., et al. Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565-574. DOI: 10.1016/s0140-6736(20)30251-8
  • 3. Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J., et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-1069. DOI: 10.1001/jama.2020.1585
  • 4. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Temporary guidelines. Version 10 (02.08.2021). M.: Ministry of Health of the Russian Federation; 2021. Available at: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/054/588/original/Временные_МР_COVID-19_%28v.10%29-08.02.2021_%281%29.pdf. Accessed March 13, 2021. Russian.
  • 5. Bubnova M.G., Aronov D.M. COVID-19 and сardiovascular diseases: from epidemiology to rehabilitation. Pul’monologiya. 2020;30(5):688-699. Russian. DOI: 10.18093/0869-0189-2020-30-5-688-699
  • 6. Sharma A., Hofmeyr A., Bansal A., Thakkar D., Lam L., Harrington Z., et al. COVID-19 associated pulmonary aspergillosis (CAPA): An Australian case report. Med Mycol Case Rep. 2021;31:6-10. DOI: 10.1016/j.mmcr.2020.06.002
  • 7. Fernandez N.B., Caceres D.H., Beer K.D., Irrazabal C., Delgado G., Farias L., et al. Ventilator-associated pneumonia involving Aspergillus flavus in a patient with coronavirus disease 2019 (COVID-19) from Argentina. Med Mycol Case Rep. 2020;31(10):19-23. DOI: 10.1016/j.immer.2020.07.001
  • 8. Abdalla S., Al-Maslamani M.A., Hashim S.M., Ibrahim A.S., Omrani A.S. Fatal Coronavirus Disease 2019-associated pulmonary aspergillosis; a report of two cases and review of the literature. IDCases. 2020;22:e00935. DOI: 10.1016/j.idcr.2020.e00935
  • 9. Salehi M., Khajavirad N., Seifi A., Salahshour F., Jahanbin B., Kazemizadeh H., et al. Proven Aspergillus flavus pulmonary aspergillosis in a COVID-19 patient: a case report and review of the literature. Mycoses. 2021;64(8):809-816. DOI: 10.1111/myc.13255
  • 10. Galstyan G.M. Coagulopathy in COVID-19. Pul’monologiya. 2020;30(5):645-657. Russian. DOI: 10.18093/0869-0189-2020-30-5-645-657
  • 11. Yaqinuddin A., Kashir J. Innate immunity in COVID-19 patients mediated by NKG2A receptors, and potential treatment using monalizumab, cholroquine, and antiviral agents. Med Hypotheses. 2020;140:109777. DOI: 10.1016/j.mehy.2020.109777
  • 12. Kostinov M.P., Markelova E.V., Svitich O.A., Polishchuk V.B. Immune mechanisms of SARS-CoV-2 and potential drugs in the prevention and treatment of COVID-19. Pul’monologiya. 2020;30(5):700-708. Russian. DOI: 10.18093/0869-0189-2020-30-5-700-708
  • 13. Koehler P., Bassetti M., Chakrabarti A. Chen S., Colombo A., Hoenigl M., et al. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis. 2020;21(6):e149-e162. DOI: 10.1016/S1473-3099(20)30847-1
  • 14. Samsonova M.V., Chernyaev A.L., Omarova Zh.R., Pershina E.A., Mishnev O.D., Zayratyants O.V., et al. Features of pathological anatomy of lungs at COVID-19. Pul’monologiya. 2020;30(5):519-532. Russian. DOI: 10.18093/0869-0189-2020-30-5-519-532
  • 15. Chuchalin A.G., ed. Pulmonology. National Guide. Short Edition. M.: GEOTAR-Media 2020. 768 p. Russian.
  • 16. Marr K.A., Platt A., Tornheim J.A. Zhang S.X., Datta K., Cardozo C., Garcia-Vidal C. Aspergillosis complicating severe coronavirus disease. Emerg Infect Dis. 2021;27(1):18-25. DOI: 10.3201/eid2701.202896
  • 17. Ghelfenstein-Ferreira T., Saade A., Alanio A., Bretagne S., Araujo de Castro R., Hamane S., et al. Recovery of a triazole-resistant Aspergillus fumigatus in respiratory specimen of COVID-19 patient in ICU – a case report. Med Mycol Case Rep. 2021;31:15-18. DOI: 10.1016/j.mmcr.2020.06.006
  • 18. Machado M., Valerio M., Álvarez-Uría A., Olmedo M., Veintimilla C., Padilla B., et al. Invasive pulmonary aspergillosis in the COVID-19 era: an expected new entity. Mycoses. 2021;64(2):132-143. DOI: 10.1111/myc.13213
  • 19. Marr K.A, Platt A., Tornheim J.A., Zhang S.X., Datta K., Cardozo C., Garcia-Vidal C. Aspergillosis complicating severe coronavirus disease. Emerg Infect Dis. 2021;27(1):18-25. DOI: 10.3201/eid2701.202896
  • 20. Chih-Cheng Lai, Weng-Liang Yu. COVID-19 associated with pulmonary aspergillosis: a literature review. J Microbiol Immunol Infect. 2020;54(1):46-53. DOI: 10.1016/j.jmii.2020.09.004
  • 21. Borman A.M., Palmer M.D., Fraser M., Patterson Z., Mann C., Oliver D., et al. COVID-19-Associated invasive aspergillosis: data from the UK National Mycology Reference Laboratory. J Clin Microbiol. 2020;59(1):e02136-20. DOI: 10.1128/JCM.02136-20
  • 22. Costantini C., Veerdonk van de F.L., Romani L. Covid-19-associated pulmonary aspergillosis: the other side of the coin. Vaccines (Basel). 2020;8(4):713. DOI: 10.3390/vaccines8040713
  • 23. Arastehfar A., Carvalho A., Veerdonk van de F.L., Jenks J.D., Koehler P., Krause R., et al. COVID-19 Associated Pulmonary Aspergillosis (CAPA) – from immunology to treatment. J Fungi (Basel). 2020;6(2):91. DOI: 10.3390/jof6020091
  • 24. Mohamed A., Rogers T.R., Talento A.F. COVID-19 associated invasive pulmonary aspergillosis: diagnostic and therapeutic challenges. J Fungi (Basel). 2020;6(3):115. DOI: 10.3390/jof6030115
  • 25. Abdalla S., Almaslamani M., Hashim S., Ibrahim A., Omrani A. Fatal coronavirus disease 2019-associated pulmonary aspergillosis; a report of two cases and review of the literature. IDCases. 2020;22:e00935. DOI: 10.1016/j.idcr.2020.e00935
Views
0 Abstract
0 PDF
0 Crossref citations
Shared